Article Text

PDF

Plasma Adropin Levels Predict Endothelial Dysfunction Like Flow-Mediated Dilatation in Patients With Type 2 Diabetes Mellitus
  1. Mustafa Topuz, MD*,
  2. Ahmet Celik, MD,
  3. Tutku Aslantas, MD,
  4. Ayse Kevser Demir, MD§,
  5. Suna Aydin, MD,
  6. Suleyman Aydin, MD
  1. From the *Department of Cardiology, Turhal State Hospital, Tokat, Turkey; †Department of Cardiology, Mersin University Medical Faculty, Mersin, Turkey; ‡Departments of Microbiology, and §Internal Medicine, Turhal State Hospital, Tokat, Turkey; ∥Department of Cardiovascular Surgery, Elazig Education and Research Hospital, Elazig, Turkey; and ¶Department of Biochemistry, Firat University Medical Faculty, Elazig, Turkey.
  1. Received June 11, 2013, and revised August 13, 2013.
  2. Accepted for publication August 13, 2013.
  3. Reprints: Ahmet Celik, MD, Department of Cardiology, Mersin University Medical Faculty, Mersin, Turkey. E-mail: ahmetcelik39{at}hotmail.com.
  4. Not supported by any funding.
  5. The authors declared no conflicts of interest.

Abstract

Objective This study investigated the role of plasma adropin levels to show endothelial dysfunction in individuals with type 2 diabetes mellitus and to compare these with flow-mediated dilatation.

Methods A total of 92 individuals with diagnosed type 2 diabetes mellitus were included and divided into 2 groups according to their brachial flow-mediated dilatation. The endothelial dysfunction group consisted of 46 participants with flow-mediated dilatation change of less than 7%, whereas 46 participants with flow-mediated dilatation change of more than 7% were accepted as the nonendothelial dysfunction group. Venous blood samples were taken from all study participants, and plasma adropin levels were measured using an enzyme-linked immunosorbent assay kit.

Results The mean flow-mediated dilatation values were 13.2% ± 4.9% in the nonendothelial dysfunction group, and 3.5% ± 3.4% in the endothelial dysfunction group. Mean hemoglobin A1c levels were significantly higher in the endothelial dysfunction group than in the nonendothelial dysfunction group (8.7% ± 1.9% vs 7.9% ± 1.6%, respectively; P < 0.038). Mean plasma adropin levels were 3.04 ± 0.79 ng/mL in the endothelial dysfunction group and 4.67 ± 1.43 ng/mL in the nonendothelial dysfunction group; P < 0.001. Plasma adropin levels showed no correlation with body mass index (r = −0.072, P = 0.497) but were positively correlated with flow-mediated dilatation values (r = 0.537, P < 0.001). In the linear regression analysis, adropin and hemoglobin A1c were independent risk factors for endothelial dysfunction in individuals with type 2 diabetes mellitus.

Conclusion Adropin is a new marker for use in demonstrating endothelial dysfunction.

Key Words
  • Adropin
  • flow-mediated dilatation
  • endothelial dysfunction
  • type 2 diabetes mellitus
  • endothelium

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.